Oncolytics Biotech (ONCY) Projected to Announce Quarterly Earnings on Wednesday

Oncolytics Biotech (NASDAQ:ONCY) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Oncolytics Biotech to announce earnings of ($0.0539) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). On average, analysts expect Oncolytics Biotech to post ($0.29) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Oncolytics Biotech Price Performance

NASDAQ ONCY opened at $0.39 on Wednesday. Oncolytics Biotech has a 1-year low of $0.38 and a 1-year high of $1.30. The firm has a market capitalization of $51.14 million, a P/E ratio of -1.15 and a beta of 1.26. The business’s 50-day simple moving average is $0.65 and its 200-day simple moving average is $0.86.

Wall Street Analyst Weigh In

Several research firms recently commented on ONCY. HC Wainwright cut their price target on shares of Oncolytics Biotech to $5.00 and set a “buy” rating on the stock in a report on Wednesday, August 19th. Weiss Ratings downgraded shares of Oncolytics Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 26th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.00.

About Oncolytics Biotech

Oncolytics Biotech Inc is a clinical-stage biotechnology company developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational, intravenously delivered reovirus designed to selectively infect and destroy certain tumor cells while stimulating an immune response against cancer.

Oncolytics is evaluating pelareorep in combination with other cancer treatments, including chemotherapy, hormonal therapies and immune checkpoint inhibitors. Its research has focused primarily on breast cancer and gastrointestinal cancers, including pancreatic cancer, with development programs intended to assess the therapy’s potential across multiple tumor types.

Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Alberta, and conducts clinical and corporate activities in North America and other regions through its research and development programs.